Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
| Image |  |
|---|---|
| Description | article |
| Author/s |
author: Andrew Zannettino Deborah L. White |
| Publication date | August 30, 2007 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |